Tucson, AZ, November 03, 2019 --(PR.com
)-- NuvOx Pharma, Inc, a clinical stage biopharmaceutical company developing NanO2TM emulsion for oxygen delivery today announced the issuance of US Patent 10,456,468 – Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic. NanO2TM emulsion is designed to increase tumor oxygen levels to make tumors more sensitive to radiation therapy and chemotherapy, and the new patent covers the technology for these applications.
Evan Unger MD, CEO of NuvOx, said, “Radiation therapy and chemotherapy are very common treatments for many types of solid tumors, but most solid tumors are hypoxic which limits the efficacy of these treatments. Our drug has a novel mechanism designed to increase tumor oxygen levels to make tumors more sensitive to these treatments. We are pleased that the US Patent office has issued this important patent to complement the rest of our intellectual property portfolio.”
The National Cancer Institute has awarded a grant to test NanO2TM emulsion Phase II clinical trial in the brain tumor, glioblastoma. These tumors are commonly hypoxic and radiation therapy and chemotherapy are both part of the standard of care.
NuvOx is a privately held biotechnology company based in Tucson, Arizona, that has clinical programs for NanO2TM emulsion in both glioblastoma and stroke. For further information, please contact John McGonigle at firstname.lastname@example.org.
Disclaimer: Certain statements in this release may constitute “forward-looking statements.” Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.